Cambridge, MA — February 3, 2026 — Leads & Copy — Bicycle Therapeutics plc (NASDAQ: BCYC) has announced leadership transitions to support its next phase of innovation. The pharmaceutical company is known for its work in bicyclic peptide (Bicycle®) technology.
Travis Thompson has been appointed as Bicycle’s chief financial officer (CFO). Thompson previously served as Bicycle’s senior vice president and chief accounting officer, beginning in April 2018. He previously worked at EY in its life sciences practice. In his new role, Thompson will continue to oversee finance and accounting functions, and now investor relations. Alethia Young, the outgoing CFO, will remain with Bicycle in an interim capacity for three months and will then continue as a company advisor.
Michael Method, M.D., MPH, MBA, has been promoted to chief medical officer (CMO). Method joined Bicycle in June 2025 and most recently served as Bicycle’s senior vice president, clinical development. As CMO, he will oversee all clinical development and the relationship with Bicycle’s Clinical Advisory Board. Method is an academic and clinical oncologist with drug development experience at oncology companies including ImmunoGen and Eli Lilly. Eric Westin, M.D., who has retired from his role as CMO, will continue with Bicycle as a distinguished fellow.
Michael Skynner will now serve as chief scientific officer. Skynner joined Bicycle in January 2016 and most recently served as Bicycle’s chief technology officer. He will oversee scientific discovery, early-stage pipeline development and the relationship with Bicycle’s Research and Innovation Advisory Board.
Bicycle Therapeutics CEO Kevin Lee, Ph.D., stated that the company made progress in 2025 and is focused on its 2026 priorities. Lee believes the evolved leadership team will help the company build momentum across its pipeline and create shareholder value. He also thanked Alethia and Eric for helping the company obtain a strong financial position and advance its clinical trials.
Bicycle Therapeutics is focused on targeted oncology clinical programs that include its new radiopharmaceutical strategic partnerships. The company expects its financial runway to extend into 2028.
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle® molecules for diseases underserved by existing therapeutics. Bicycle molecules are synthetic short peptides constrained with small molecule scaffolds. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Drug Conjugate (BDC®) targeting Nectin-4; BT5528, a BDC molecule targeting EphA2; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. The company is also developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology through various partnerships.
Bicycle Therapeutics is headquartered in Cambridge, UK, with key functions and leadership in Cambridge, Mass.
Source: Bicycle Therapeutics
